To assess potential complement activation in FD patient groups, we determined the concentration of small cleavage fragments of C3 and C5, i.e. the C3a and C5a anaphylatoxins, in the serum of treatment-naiüve FD patients and ERT-treatment. The gene discussed is C5; the disease is Fabry disease.